Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today

Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today

OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:

   
What: Transgenomic, Inc. First Quarter 2013 Financial Results and Business Update Conference Call
 
When: Wednesday, May 8, 2013 @ 5:00 p.m. Eastern
 
Where:

http://www.transgenomic.com/calendar/2013/04/first-quarter-financial-results-conference-call-may-8-2013

 
How: Live over the Internet -- Simply log on to the web at the address above.
 
Contact: Investor Relations, 402-452-5416
 

To access the call via telephone, dial 866-952-1907 from the U.S. and Canada or 785-424-1826 for international participants and enter conference ID TRANS. A telephone replay will be available from 8:00 p.m. Eastern Time on May 8, 2013 through 11:59 p.m. Eastern Time on May 22, 2013 by dialing 800-839-1198 (domestic) or 402-220-0458 (international).


About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.



Investor Contact
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com
or
Company Contact
Transgenomic, Inc.
Investor Relations, 402-452-5416
investorrelations@transgenomic.com

KEYWORDS:   United States  North America  Nebraska

INDUSTRY KEYWORDS:

The article Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to Preferred Shares

Learn the difference between preferred and common shares.

View Course »

Professional Vs Do it Yourself Investing

Should you get advice or DYI?

View Course »

Add a Comment

*0 / 3000 Character Maximum